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Summary WHT/Ht mice were transplanted s.c. with NC carcinoma, and the tumours were excised after 2
weeks. The mice were treated orally throughout the experiments with prednisolone 500pgkg-' or mepacrine
3.6mgkg-1, starting the day after tumour transplantation or, with prednisolone, the day after tumour
excision. In some experiments the mice were also treated with the cytotoxic drugs methotrexate 2mgkg 1 and
melphalan 1.4mgkg-1. The excised tumours were weighed; some of them, and samples of serum, were
extracted for prostanoids which were measured by radioimmunoassay. The chemotherapy lengthened the
survival of the mice, but prednisolone or mepacrine had little or no effect on survival, metastasis, the
response to chemotherapy, tumour size or the formation of tumour prostanoids.
Prostaglandin synthesis inhibitors have been extensively
investigated in various murine cancers, and they usually
show a beneficial effect (Bennett, 1982; 1986). In the NC
tumour model the prostaglandin synthesis inhibitors indo-
methacin or flurbiprofen increase mouse survival and usually
reduce tumour size. Survival is even longer when these
nonsteroidal anti-inflammatory drugs are used with the
cytotoxic drugs methotrexate and melphalan (Bennett et al.,
1982). The effects of the anti-inflammatory drugs seems
likely to result from inhibition of prostaglandin synthesis
rather than from other properties that the drugs may have
(Flower, 1974), since administration of a PGE2 analogue
counteracted the effect of indomethacin (Bennett et al.,
(1985). A similar effect might therefore be expected with other
drugs that reduce prostaglandin formation, such as corti-
costeroids and mepacrine which can inhibit phospholipase
activity and so depress the release of prostaglandin pre-
cursors (Vane et al., 1982). This action may be particularly
relevant to human cancers since prednisolone is frequently
used in chemotherapy regimens. We have therefore studied
the effects of prednisolone and mepacrine, alone and in
combination with the cytotoxic drugs methotrexate and
melphalan, in mice with NC tumours. Measurements were
made of tumour weight and prostanoid content, the
occurrence of metastases, and mouse survival.
Materials and methods
The original NC tumour arose spontaneously in the
mammary region of a WHT/Ht mouse (Hewitt et al., 1976)
and has since been passaged only in this strain. It has a high
incidence of local lymphatic spread, recurrence in the scar
following tumour excision, and metastasis mainly to the
lungs and mediastinum.
On day 0, male or female WHT/Ht mice were injected s.c.
into the left flank with - 106 NC carcinoma cells in a single-
cell suspension from passaged tumours as described
previously (Bennett et al., 1979, 1982). All tumours were
excised at 2 weeks and weighed. The study consisted of 6
separate experiments, each with 9-15 WHT/Ht mice/group.
Drugs were given orally in 0.1 ml 50% syrup BP for 5 days
(Monday to Friday) each week, and treatment with predni-
solone or mepacrine was continued until death or the end of
the experiment (day 121). The doses chosen are approxi-
mately the highest recommended amounts for man.
In experiments 1 and 2, prednisolone 500pgkg-1 (or
vehicle for controls) were given daily from day I (the day
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after tumour inoculation) to female mice. In experiment 2,
methotrexate 2mgkg-1 and melphalan 1.4mgkg-1 were
given on days 15-17, 22-24, 29-31 with or without
prednisolone.
In experiments 3 and 4, prednisolone 500pgkg-1 or
vehicle were given daily from day 15 (the day after tumour
excision) to female mice. In experiment 4, methotrexate and
melphalan were given with prednisolone or vehicle as above.
Experiments 5 and 6 were with male mice given mepacrine
hydrochloride 3.6mgkg-' from day 1, alone or with metho-
trexate and melphalan as above. There was no rationale
concerning the sex of the mice. We used what was available,
but kept to the same sex in each study.
In studies where drug treatment began on day 1, some
tumours were homogenised in acid-ethanol (Krebs solution
acidified to pH 3 with formic acid, and mixed with an
equal volume of ethanol). Homogenisation in this solution
gives 'basal' amounts of prostaglandins (Bennett et al.,
1973). After extraction (Unger et al., 1971), PGE, 6-keto-
PGF1 and TXB2 were measured by radioimmunoassay
(Hennam et al., 1974). The % cross-reactivities of the
antibodies were as follows. PGE antibody (Miles Scientific):
PGE2 100; PGE1 53; PGF2a 10; PGA1 2.7; PGF1, 2.6; PGB2
1.5; PGA2 1.4; PGB10.9. 6-Keto-PGFia antibody (Wellcome
Research Laboratories): 6-keto-PGF1a 100; PGF2a 3.0; PGE2
0.1; TXB2 0.02. TXB2 antibody: TXB2 100; PGF2a 0.11; 6-
keto-PGF,, 0.01; PGE2 <0.01. Intra- and inter-assay
coefficients of variation were respectively 10-11% and 15-
21% and the lower limits of detection were (pg per 100pg):
PGE 15.6; 6-keto-PGFI 12.5; TXB2 7.8. The tritiated
compounds, obtained from Amersham International, had the
following specific activities (TBqmmol -1): PGE2 5.92; 6-
keto-PGF1a 5.55; TXB2 6.66. The bound and unbound
compounds were separated by adding 1ml of cold (4°C)
ammonium sulphate/calcium sulphate (65% saturated
ammonium sulphate solution pH 7.6+calcium sulphate 1 g
per 25ml, maintained as an even suspension with a magnetic
stirrer).
The mice were weighed twice weekly from at least 2 weeks
prior to the start of the experiment up to death or day 121.
Those with advanced carcinomatosis were killed humanely to
prevent suffering (Bennett et al., 1982). Survival time was
measured from the day of tumour inoculation, and analysed
by the method of Lee and Desu (1972). The incidences of
recurrence in the excision scar, lymph nodes and or distant
sites were noted at postmortem, and analysed by Fisher's
exact test.
In another experiment, using 8 normal female mice/group,
we investigated the effects of mepacrine 3.6mgkg-1 or
prednisolone 500pgkg- 1 on serum prostanoids. The mice
were dosed daily for 2 days with drug or vehicle, and
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anaesthetised with ether 2h after the final dose. Blood was
obtained by cardiac puncture and incubated at 37°C for
30min to allow formation of TXB2 during clotting. After
centrifugation (1500 g, 4°C for 10min), the serum was
removed and stored at -20°C prior to radioimmunoassay of
the unextracted samples for PGE, 6-keto-PGF1, and TXB2
Results
Tumour weight, spread and host survival
All transplanted tumours became palpable within 10 days.
The weights of the tumours excised from mice treated from
day I with prednisolone (experiments 1 and 2) were similar
to the controls, being respectively 370 (240-440)mg n=30,
and 300 (250-400)mg, n=30, P>0.2 (Mann-Whitney U-
test). The weights of tumours from mice treated from day 1
with mepacrine (experiments 5 and 6) were also similar to
controls, being respectively 240 (80-460)mg n=45, and 230
(120-380) mg n =43, P>0.8.
Neither prednisolone nor mepacrine improved mouse
survival, regardless of whether treatment was started after
the tumour was transplanted or excised. In fact, mice treated
with prednisolone from day I (experiments 1 and 2) fared
worse than the controls (P<0.04, Lee & Desu 1972; Table
I). Cytotoxic chemotherapy alone (methotrexate and
melphalan) improved survival, but this was not affected by
combination with prednisolone or mepacrine (Table I).
Figure 1 shows survival curves for mice given prednisolone




Figure 1 Treatment with the cytotoxic drugs methotrexate and
melphalan (Cyto) increased the survival time of mice with
resected NC tumours (P=0.016, Lee & Desu, 1972).
Prednisolone 500pgkg-' (Drug) given from day 1, the day after
tumour transplantation, seemed to shorten the survival time
(experiments 5 and 6), but it did not affect the response to the
cytotoxic drugs (Drug+cyto).
The postmortem findings showed mainly similar incidences
of recurrence in the excision scar, lymph nodes and lungs in
the different treatment groups. The lack of effect on
metastasis in mice given chemotherapy is not surprising,
since they lived longer and had more time for tumour to
spread, grow and eventually kill them.
Tumour prostanoids
The median tumour yield of 6-keto-PGF1. (mice treated
from day 1 with prednisolone) was 36% less than controls
(P<0.1; experiment 1). In the mepacrine-treated mice
(experiment 6) the median tumour PGE and TXB2 were
respectively 38% and 25% less then controls (both P<0.1).
The other tumour prostanoid measurements were similar to
controls (Table II). PGE was the predominant tumour
prostanoid (medians for control males and females
respectively 214 and 150ngg-1), and there was little TXB2
(medians 12 and 5 ngg 1; Table II).
Serum prostanoids
The serum contained more TXB2 than PGE or 6-keto-
PGFi,a. In mice given prednisolone, the median amount of
serum TXB2 was 86% greater than control (P=0.04)
whereas 6-keto-PGF1, was 84% lower (P=0.01); the PGE
was little changed (Table III). Mepacrine-treated mice also
had less 6-keto-PGF1,, (median 74% lower than control,
P=0.04), but the other prostanoids were little affected.
Discussion
As reported previously (Bennett et al., 1982; 1985), chemo-
therapy with methotrexate and melphalan increased the
survival of mice with resected NC tumours. We started these
experiments in the expectation that prednisolone and mepa-
crine would act as phospholipase inhibitors, thereby lowering
prostaglandin production and mimicking the beneficial effect
of cyclooxygenase inhibitors in mice with NC tumours
(Bennett et al., 1979; 1982). Lynch et al. (1978) found that
indomethacin, aspirin or hydrocortisone increased the
survival of mice with methylcholanthrene-induced tumours,
although only the nonsteroids significantly reduced the
tumour size. Inhibition of prostaglandin synthesis appears to
explain the antitumour effect of indomethacin on the NC
cancer, since a stable PGE2 analogue counteracted the
increase in survival (Bennett et al., 1985). However, in the
present experiments prednisolone or mepacrine had little or
no effect on the cancer or its response to the cytotoxic drugs.
An explanation for this lack of anticancer activity may be
that although the doses/kg of prednisolone and mepacrine
are near the maximum used in man, they caused at most a
weak inhibition of prostanoid formation by the mouse
tumours. Furthermore, although they reduced the amount of
6-keto-PGF1, in serum from normal mice, the PGE seemed
Table I Mouse survival
Drug Day treated Controls Drug-treated CT Drug+CT
Prednisolone D1 39 (36-43) 37 (33-38) 45 (42-46)a 48 (42-52)
500 igkg-I n=19 n=19 n=10 n=10
Prednisolone D15 37 (35-40) 38 (35-44) 51 (51-55)b 49 (47-53)
500ugkg-1 n= 19 n=20 n=10 n=10
Mepacrine DI 41 (38-50) 39 (34-49) 52 (45-55)c 51 (47-64)
3.6mgkg-1 n=23 n=23 n=17 n=18
Prednisolone given from day 1 (D1, experiments 1 and 2) or day 15 (DI5, experiments 3
and 4) or mepacrine from DI (experiments 5 and 6) had little or no effect on mouse survival
(Lee & Desu, 1972). The results are days, shown as medians with semiquartile ranges in
parentheses. Survival was lengthened by chemotherapy (CT) with methotrexate and
melphalan, but addition ofprednisolone or mepacrine did not affect the response to CT.
P values: a =0.02 (experiment 2); b<0.005 (experiment 4); c<0.0005 (experiments 5 and 6).
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Table II Radioimmunoassay of tumour prostanoids
Treatment Sex PGE 6-Keto-PGFI, TXB2
Controls F 150 (103-193) 87 (62-154) 5 (4-8)
n=10 n=10 n=10
500 ,tg kg'- prednisolone F 102 (94-141) 56 (62-68) 4 (3-5)
n=10 n=10 n=10
Controls M 214 (120-278) 55 (39-88) 12 (9-14)
n= 19 n=20 n=20
3.6mgkg- mepacripe M 133 (88-198) 47 (32-94) 9 (8-11)
hydrochloride n= 19 n=20 n=20
In all 12 cases (experiments 1 to 6) the tumours from drug-treated mice
yielded smaller median amounts of prostanoids when homogenised in acid-
ethanol, but the P values were <0.1 compared to controls in only 3 groups
(prednisolone, 6-keto-PGF1M,; mepacrine PGE, TXB2). The results are nggt
wet issue, shown as medians with semiquartile ranges in parentheses.
Table III Serum prostanoids
PGE 6-keto-PGF,,a TXB2
Control 9 (8-11) 25 (23-27) 168 (160-175)
Prednisolone 500/gkg-' 9 (8-9) 4 (4-5)b 312 (293-390)a
Mepacrine 3.6mgkg1 11 (10-11) 9( 6-22)a 219 (127-300)
Prednisolone-treated normal female mice had less 6-keto-PGF1, and
more TXB2 in the serum samples. The same trend occurred with
mepacrine. ap=0.04 bp=0.01 (Mann-Whitney U-test). Values are ngml-1
shown as medians with semiquartile ranges in parentheses. In all groups
n=8, except for mepacrine and 6-keto-PGF1. where n=7.
to be unaffected and the amount of TXB2 was actually
greater. Rittenhouse-Simmons and Deykin (1981) considered
that failure of platelets to synthesise new protein explains
why their prostanoid formation is not blocked by corti-
costeroids. However, this may not be correct since there is
some evidence that platelets can incorporate amino acids
into protein (Shaw et al., 1984).
The possibility that the doses were too low to affect
extravascular prostanoid formation prompted us to study
prednisolone 0.5-15mgkg-1 or mepacrine 3.6-28.8mgkg-1
given orally to normal mice for 3 days. These doses had little
or no effect on the amounts of PGE, 6-keto-PGF1, or TXB2
extracted from intestine homogenised in acid-ethanol
(unpublished). Although this seems to be contrary to current
thinking (Vane et al., 1982), various groups have reported
that in vivo or with intact cells in vitro corticosteroids did not
affect prostaglandin synthesis. For example there was no
effect of dexamethasone on the amount of peritoneal prosta-
glandins in rats (Deraedt et al., 1980), or on prostaglandin
formation by rat polymorphonuclear leucocytes (Dray et al.,
1980). In patients given 6cx-methyl-prednisolone the concen-
trations of prostanoids in synovial effusions were variably
affected: 6-keto-PGF1, fell by 35% and PGF2a increased by
30%, while PGE2 and TXB2 were unchanged (Bombardieri
et al., 1981). The latter results, and our findings with mouse
serum, suggest that the effects of prednisolone and mepa-
crine are more like those expected of a PGI2 synthetase
inhibitor than a phospholipase A2 inhibitor, there being in
general less 6-keto-PGF1, and more TXB2. Clearly
inhibition of prostanoid synthesis by these drugs in vivo does
not seem to be a universal occurrence.
According to Honn et al. (1981, 1983), increasing the
prostacyclin:thromboxane ratio in blood decreases metastasis
by reducing platelet aggregation. Since this ratio decreased
with prednisolone or mepacrine, we might have expected the
drugs to worsen the cancer. Measurement of blood
prostanoids is fraught with difficulties, and furthermore we
used serum so that some of the 6-keto-PGF1c, may have
originated from PGI2 formed during clotting. Nevertheless,
our findings are weak evidence against Honn's hypothesis.
They are consistent with our finding that the thromboxane
synthetase inhibitor dazmegrel reduced mouse serum TXB2
and increased the 6-keto-PGF1,, but had no effect on the
survival of mice bearing NC tumours (Stamford et al., 1986).
Similarly, recent work in breast cancer patients demonstrated
that the TXB2:6-keto-PGF1, ratio in the systemic circulation
is not an indicator of malignancy or metastasis (Nigam et
al., 1985).
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